Eckert & Ziegler Strahlen- und Medizintechnik AG announced that to expand its manufacturing capacities, Eckert & Ziegler plans to invest around ?10 million in its own site in Wilmington, MA. Eckert & Ziegler is thus positioning itself as an important supplier of lutetium-177 in the rapidly growing radioligand therapy market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.66 EUR | +1.33% | -1.17% | +10.56% |
May. 15 | ECKERT & ZIEGLER : Hauck & Aufhauser reiterates its Buy rating | ZD |
May. 14 | Eckert & Ziegler SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.56% | 1.03B | |
+3.20% | 7.63B | |
-6.99% | 4.53B | |
-4.77% | 2.98B | |
+8.82% | 2.19B | |
-30.15% | 1.07B | |
-47.58% | 829M | |
+4.09% | 905M | |
-29.15% | 696M | |
-19.25% | 719M |
- Stock Market
- Equities
- EUZ Stock
- News Eckert & Ziegler SE
- Eckert & Ziegler Strahlen- und Medizintechnik AG Announces Plans to Invest Around ? 10 Million in its Own Site in Wilmington